American Vanguard Reports Third Quarter 2026 Results
International sales fell 17% in the quarter, while nine-month interest expense increased to $24.066 million from $13.135 million.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
American Vanguard (AVD) reported a third-quarter 2026 net loss of $17.7 million as sales declined and gross margin contracted. Sales fell 9% year over year to $108.376 million, while gross margin decreased to 24% from 29%. Loss per share widened to $0.61 from $0.43. Adjusted EBITDA, a non-GAAP earnings measure excluding interest, taxes, depreciation, amortization and certain other items, was breakeven versus $8.3 million.
The company revised its full-year outlook to $500 million–$530 million in sales and $36 million–$40 million in adjusted EBITDA. It acquired four U.S. brands and registrations from Syngenta and entered a distribution agreement with Sipcam Agro. American Vanguard targets $100 million in annualized new-product revenue by 2030. Nine-month sales fell 4% to $348.698 million, and net loss widened to $31.682 million from $21.669 million.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Revised full-year outlook calls for $500 million–$530 million sales and $36 million–$40 million adjusted EBITDA.
- Moderate point. Forward-looking: it has not happened yet and may not happen.New-product revenue goal targets $100 million annualized by 2030.
- Moderate pointCash increased to $83.909 million at September 30, 2026, from $12.425 million at December 31, 2025.
- Moderate pointNet trade working capital improved $22 million, or 14%, versus the prior-year period.
- Moderate pointThird-quarter product liability expense fell to $0.022 million from $7.029 million year over year.
11 minor points
- Minor pointPortfolio expansion included four U.S. brands and registrations acquired from Syngenta at third-quarter end.
- Minor pointDistribution agreement with Sipcam Agro expands American Vanguard's portfolio.
- Minor pointThird-quarter customer prepayments increased 44% year over year.
- Minor pointNine-month U.S. Crop sales increased 3% to $157.510 million year over year.
- Minor pointNine-month U.S. Specialty sales increased 6% to $57.045 million year over year.
- Minor pointThird-quarter selling, general and administrative expenses fell to $25.797 million from $26.747 million year over year.
- Minor pointNine-month selling, general and administrative expenses fell to $80.133 million from $81.998 million year over year.
- Minor pointThird-quarter research, development and regulatory expenses fell to $5.342 million from $5.654 million year over year.
- Minor pointNine-month research, development and regulatory expenses fell to $17.097 million from $17.139 million year over year.
- Minor pointNine-month product liability expense fell to $0.223 million from $7.029 million year over year.
- Minor pointNine-month operating loss narrowed to $6.380 million from $6.449 million year over year.
Negative
- Major pointThird-quarter net loss widened to $17.668 million; loss per share increased to $0.61 from $0.43.
- Major pointLong-term debt excluding current maturities rose to $263.937 million from $174 million at year-end 2025.
- Moderate pointThird-quarter sales fell 9% to $108.376 million year over year.
- Moderate pointThird-quarter gross profit fell 23% to $26.252 million; gross margin decreased to 24% from 29%.
- Moderate pointThird-quarter operating loss widened to $7.965 million from $6.505 million year over year.
- Moderate pointThird-quarter adjusted EBITDA declined to breakeven from $8.3 million year over year.
- Moderate pointThird-quarter net interest expense increased to $9.146 million from $4.920 million year over year.
- Moderate pointStockholders' equity fell to $163.123 million from $192.397 million at year-end 2025.
13 minor points
- Minor pointThird-quarter international sales fell 17% to $47.188 million year over year.
- Minor pointThird-quarter U.S. Crop sales fell 2% to $42.316 million year over year.
- Minor pointThird-quarter U.S. Specialty sales fell 2% to $18.872 million year over year.
- Minor pointNine-month sales fell 4% to $348.698 million year over year.
- Minor pointNine-month international sales fell 14% to $134.143 million year over year.
- Minor pointNine-month gross profit fell 5% to $99.382 million, with gross margin unchanged at 29%.
- Minor pointNine-month net loss widened to $31.682 million; loss per share increased to $1.10 from $0.76.
- Minor pointNine-month net interest expense increased to $24.066 million from $13.135 million year over year.
- Minor pointCurrent debt maturities reached $3.750 million at September 30, 2026, versus none at year-end 2025.
- Minor pointThird-quarter CFO transition costs totaled $1.316 million, versus none in the prior-year quarter.
- Minor pointThird-quarter transformation expense increased to $1.665 million from $1.442 million year over year.
- Minor pointNine-month transformation expense increased to $5.975 million from $5.254 million year over year.
- Minor pointNine-month asset impairments increased to $0.943 million from $0.227 million year over year.
News Explained
At September 30, cash was $83,909 thousand, while long-term and current debt were $263,937 thousand and $3,750 thousand.
American Vanguard has reported its third-quarter results; net interest expense for the quarter was
At
Key Figures
- Net sales
- $108.376M vs. $119.313M
- Q3 2026 vs. Q3 2025
- Gross margin
- 24% vs. 29%
- Q3 2026 vs. Q3 2025
- Operating loss
- $7.965M vs. $6.505M
- Q3 2026 vs. Q3 2025
- Net loss
- $17.668M vs. $12.358M
- Q3 2026 vs. Q3 2025
- Adjusted EBITDA
- Breakeven vs. $8.3M
- Q3 2026 vs. Q3 2025
- EPS
- ($0.61) vs. ($0.43)
- Q3 2026 vs. Q3 2025
- FY2026 outlook
- Adjusted EBITDA $36M–$40M on sales of $500M–$530M
- Revised full-year outlook
Previous Earnings Reports
-
Reaffirmed FY2026 adjusted EBITDA guidance of $44–48 million on sales of $530–550 million.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adjusted ebitda financial
non-gaap financial measures financial
negative operating leverage financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, CA / ACCESS Newswire / November 9, 2026 / American Vanguard Corporation, a diversified specialty and agricultural products company that develops, manufactures, and markets solutions for crop protection and nutrition, turf and ornamental management and commercial pest control, today reported financial results for the third quarter and nine-months ended September 30, 2026.
Third Quarter 2026 Financial and Operational Highlights - versus Third Quarter 2025
- Net sales of
$108 million as compared to$119 million ; - Gross profit margin of
24% , as compared to29% ; - Operating loss of
$8.0 million , as compared to operating loss of$6.5 million ; - Net loss of
$17.7 million , as compared to$12.4 million ; - Breakeven Adjusted EBITDA[1] as compared to
$8.3 million ; - EPS of (
$0.61) , as compared to ($0.43) - Revise Full-Year Outlook; Adjusted EBITDA
$36 million to$40 million on Sales of$500 million to$530 million
Dak Kaye, CEO of American Vanguard, stated, "Our actions are taking hold, and the progress we are making across American Vanguard continues to build, even as market conditions remain difficult, particularly outside the U.S., where El Niño is materially impacting our business this year. In the U.S., our largest and most important market, we continue to outperform our peers in a challenging environment. The cost actions we took in the first half, including the rationalization of our Los Angeles facility and the relocation of our headquarters are beginning to deliver operational savings. In the near term, however, those savings have been more than offset by a sharp rise in diesel and other transportation costs arising from instability in the Middle East. We are working to recover gross margins through commercial actions."
Mr. Kaye continued, "Importantly, we are building a new product engine that we believe will drive growth over the next several years. At the end of the third quarter, we acquired four U.S. brands and registrations from Syngenta® and entered into a distribution agreement with Sipcam Agro, which together meaningfully expand our portfolio. Combined with our pipeline of new product launches, these additions support our goal of driving
Matt Horwath, Chief Financial Officer, stated, "We began to see progress this quarter in terms of lower operating costs and improved manufacturing efficiencies as a result of actions taken earlier this year. However, this progress was more than offset in the quarter by the effects of negative operating leverage, driven by lower international sales and higher raw material and transportation costs. Net trade working capital improved by
Earnings Conference Call
The company will be hosting an earnings conference call on November 9, 2026 at 5:00 pm Eastern Time/2:00 pm Pacific Time.
The conference call will be webcast on the Company's website at https://www.investors-american vanguard.com/ or by going to the following link: https://www.webcaster5.com/Webcast/Page/3070/54771
If you are unable to listen live, the conference call will be archived for one year and may be accessed using the company's website: https://www.investors-american-vanguard.com/
About American Vanguard
American Vanguard Corporation is a diversified specialty and agriculture products company that develops and markets products for crop protection and management, turf and ornamentals management, and public health. Over the past 20 years, through product and business acquisitions, the Company has significantly expanded its operations and now has more than 1,000 product registrations worldwide. To learn more about the Company, please reference www.american-vanguard.com.
The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this release the matters set forth in this press release include forward-looking statements. These statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward looking statements often use words such as "believe," "expect," "anticipate," "intend," "estimate," "project," "outlook," "forecast," "target," "trend," "plan," "goal," or other words of comparable meaning or future-tense or conditional verbs such as "may," "will," "should," "would," or "could." These forward-looking statements are based on the current expectations and estimates by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include risks detailed from time-to-time in the Company's SEC reports and filings. All forward-looking statements, if any, in this release represent the Company's judgment as of the date of this release. The company disclaims any intent or obligation to update these forward-looking statements.
Non-GAAP Financial Measures
In addition to providing results that are determined in accordance with accounting principles generally accepted in the United States of America (GAAP), we present Adjusted EBITDA and Adjusted operating expenses, which are non-GAAP financial measures. These measures should not be considered in isolation or as an alternative to GAAP measures such as net income, or diluted earnings per share, as applicable, or other financial statement data presented in our financial statements as an indicator of our financial performance or liquidity.
We define EBITDA as net (loss) income, adjusted for depreciation and amortization, provision for income taxes and interest expense. We define Adjusted EBITDA as EBITDA as further adjusted for stock compensation expense and for certain items management believe are not reflective of the underlying operations of our business, including but not limited to the exclusion of charges that are considered by management to be unusual and not representative of the Company's underlying performance and future prospects. In 2026 and 2025 that included non-recurring expenses. The resulting Adjusted EBITDA measure is aligned with the Company's metric for its credit facility agreement in the applicable periods.
We define Adjusted operating expense as operating expenses as further adjusted for stock compensation expense and for certain items management believe are not reflective of the underlying operations of our business, including but not limited to the exclusion of charges that are considered by management to be unusual and not representative of the Company's underlying performance and future prospects as well as the amortization expense for intangibles assets related to acquired product lines.
We use Adjusted EBITDA and Adjusted operating expenses to assess the operating results and effectiveness and efficiency of our business. We present this non-GAAP financial measure because we believe that investors consider Adjusted EBITDA and Adjusted operating expenses to be an important supplemental measure of performance, and we believe that this measure is frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. As the Company continues to work through its transformation efforts, management believes that presenting Adjusted EBITDA and Adjusted operating expenses provides an effective comparison between the Company and its industry peers. Non-GAAP financial measures as reported by us may not be comparable to similarly titled metrics reported by other companies and may not be calculated in the same manner. These measures have limitations as analytical tools, and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP.
The Company is not able to provide a reconciliation without unreasonable efforts of its forward-looking guidance related to Adjusted EBITDA and Adjusted operating expenses to the most directly comparable GAAP financial measure due to the inherent difficulty in predicting with reasonable certainty the timing and amount of certain items that are excluded from Adjusted EBITDA and Adjusted operating expenses, such as share-based compensation, acquisition-related expenses, and foreign exchange gains or losses, which could be material to the Company's results computed in accordance with GAAP.
Investor Representative
Alpha IR Group
Robert Winters
Robert.winters@alpha-ir.com
(917) 821-6305
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share data) (Unaudited)
ASSETS | September 30, 2026 | December 31, 2025 | ||||||
Current assets: | ||||||||
Cash | $ | 83,909 | $ | 12,425 | ||||
Receivables: | ||||||||
Trade, net of allowance for credit losses of | 142,677 | 160,511 | ||||||
Other | 7,522 | 7,278 | ||||||
Total receivables, net | 150,199 | 167,789 | ||||||
Inventories | 194,079 | 176,034 | ||||||
Prepaid expenses | 8,464 | 9,668 | ||||||
Income taxes receivable | 1,750 | 4,606 | ||||||
Total current assets | 438,401 | 370,522 | ||||||
Property, plant and equipment, net | 51,956 | 53,036 | ||||||
Operating lease right-of-use assets, net | 16,407 | 16,793 | ||||||
Intangible assets, net | 139,809 | 138,746 | ||||||
Deferred income tax assets | 2,963 | 2,637 | ||||||
Other assets | 13,874 | 14,803 | ||||||
Total assets | $ | 663,410 | $ | 596,537 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 86,325 | $ | 87,505 | ||||
Customer prepayments | 44,621 | 33,094 | ||||||
Accrued program costs | 46,825 | 52,227 | ||||||
Accrued expenses and other payables | 26,704 | 28,261 | ||||||
Current portion of long-term debt | 3,750 | - | ||||||
Operating lease liabilities, current | 5,637 | 5,765 | ||||||
Income taxes payable | 3,370 | 2,594 | ||||||
Total current liabilities | 217,232 | 209,446 | ||||||
Long-term debt, net of current portion | 263,937 | 174,000 | ||||||
Operating lease liabilities, long-term | 11,243 | 11,621 | ||||||
Deferred income tax liabilities | 7,115 | 8,150 | ||||||
Other liabilities | 760 | 923 | ||||||
Total liabilities | 500,287 | 404,140 | ||||||
Commitments and contingent liabilities | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, | - | - | ||||||
Common stock, | 3,496 | 3,492 | ||||||
Additional paid-in capital | 118,378 | 117,106 | ||||||
Accumulated other comprehensive loss | (10,869 | ) | (12,000 | ) | ||||
Retained earnings | 123,319 | 155,000 | ||||||
| 234,324 | 263,598 | |||||||
Less treasury stock at cost, 5,915,182 shares at September 30, 2026 and December 31, 2025 | (71,201 | ) | (71,201 | ) | ||||
Total stockholders' equity | 163,123 | 192,397 | ||||||
Total liabilities and stockholders' equity | $ | 663,410 | $ | 596,537 | ||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Net sales | $ | 108,376 | $ | 119,313 | $ | 348,698 | $ | 364,426 | ||||||||
Cost of sales | (82,124 | ) | (85,099 | ) | (249,316 | ) | (259,474 | |||||||||
Gross profit | 26,252 | 34,214 | 99,382 | 104,952 | ||||||||||||
Operating expenses | ||||||||||||||||
Selling, general and administrative | (25,797 | ) | (26,747 | ) | (80,133 | ) | (81,998 | |||||||||
Research, product development and regulatory | (5,342 | ) | (5,654 | ) | (17,097 | ) | (17,139 | |||||||||
Product liability claims | (22 | ) | (7,029 | ) | (223 | ) | (7,029 | |||||||||
CFO transition costs | (1,316 | ) | - | (1,316 | ) | - | ||||||||||
Transformation | (1,665 | ) | (1,442 | ) | (5,975 | ) | (5,254 | |||||||||
Asset impairments | - | (93 | ) | (943 | ) | (227 | ||||||||||
(Loss) gain from sale of assets | (75 | ) | 246 | (75 | ) | 246 | ||||||||||
Operating loss | (7,965 | ) | (6,505 | ) | (6,380 | ) | (6,449 | |||||||||
Change in fair value of an equity investment | (21 | ) | (511 | ) | (193 | ) | (511 | |||||||||
Interest expense, net | (9,146 | ) | (4,920 | ) | (24,066 | ) | (13,135 | |||||||||
Loss before provision for income taxes | (17,132 | ) | (11,936 | ) | (30,639 | ) | (20,095 | |||||||||
Income tax expense | (536 | ) | (422 | ) | (1,043 | ) | (1,574 | |||||||||
Net loss | $ | (17,668 | ) | $ | (12,358 | ) | $ | (31,682 | ) | $ | (21,669 | |||||
Net loss per common share-basic | $ | (0.61 | ) | $ | (0.43 | ) | $ | (1.10 | ) | $ | (0.76 | |||||
Net loss per common share-assuming dilution | $ | (0.61 | ) | $ | (0.43 | ) | $ | (1.10 | ) | $ | (0.76 | |||||
Weighted average shares outstanding-basic | 28,775 | 28,511 | 28,691 | 28,377 | ||||||||||||
Weighted average shares outstanding-assuming dilution | 28,775 | 28,511 | 28,691 | 28,377 | ||||||||||||
AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES
ANALYSIS OF SALES
(In thousands)
(Unaudited)
| For the Three Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | Change | % Change | |||||||||||||
Net sales: | ||||||||||||||||
U.S. Crop | $ | 42,316 | $ | 43,310 | $ | (994 | ) | -2 | % | |||||||
U.S. Specialty | 18,872 | 19,233 | (361 | ) | -2 | % | ||||||||||
Total U.S. | 61,188 | 62,543 | (1,355 | ) | -2 | % | ||||||||||
International | 47,188 | 56,770 | (9,582 | ) | -17 | % | ||||||||||
Total net sales | $ | 108,376 | $ | 119,313 | $ | (10,937 | ) | -9 | % | |||||||
Total cost of sales | $ | (82,124 | ) | $ | (85,099 | ) | $ | 2,975 | -3 | % | ||||||
Total gross profit | $ | 26,252 | $ | 34,214 | $ | (7,962 | ) | -23 | % | |||||||
Total gross margin | 24 | % | 29 | % | ||||||||||||
| For the Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | Change | % Change | |||||||||||||
Net sales: | ||||||||||||||||
U.S. Crop | $ | 157,510 | $ | 153,511 | $ | 3,999 | 3 | % | ||||||||
U.S. Specialty | 57,045 | 54,067 | 2,978 | 6 | % | |||||||||||
Total U.S. | 214,555 | 207,578 | 6,977 | 3 | % | |||||||||||
International | 134,143 | 156,848 | (22,705 | ) | -14 | % | ||||||||||
Total net sales | $ | 348,698 | $ | 364,426 | $ | (15,728 | ) | -4 | % | |||||||
Total cost of sales | $ | (249,316 | ) | $ | (259,474 | ) | $ | 10,158 | -4 | % | ||||||
Total gross profit | $ | 99,382 | $ | 104,952 | $ | (5,570 | ) | -5 | % | |||||||
Total gross margin | 29 | % | 29 | % | ||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
| For the Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (31,682 | ) | $ | (21,669 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization of property, plant and equipment and intangible assets | 13,442 | 14,007 | ||||||
Amortization of other long-term assets | 5 | 16 | ||||||
Loss (gain) on disposal of property, plant and equipment | 75 | (246 | ) | |||||
Provision for estimated credit losses | 2,469 | 1,944 | ||||||
Stock-based compensation | 901 | 1,741 | ||||||
Deferred income taxes | (1,073 | ) | (353 | ) | ||||
Change in liabilities for uncertain tax positions or unrecognized tax benefits | (127 | ) | (522 | ) | ||||
Change in equity investment fair value | 193 | 511 | ||||||
Impairment of assets | 943 | 227 | ||||||
Payment-in-kind debt leverage fee | 1,261 | - | ||||||
Amortization of deferred loan fees | 2,899 | 1,167 | ||||||
Lease obligations and non-cash lease expense, net | (120 | ) | (150 | ) | ||||
Unrealized foreign currency transaction losses (gains) | 243 | (704 | ) | |||||
Changes in assets and liabilities associated with operations: | ||||||||
Decrease in net receivables | 14,812 | 935 | ||||||
Increase in inventories | (16,007 | ) | (16,513 | ) | ||||
Increase in prepaid expenses and other assets | (1,039 | ) | (965 | ) | ||||
Change in income tax receivable and payable, net | 3,526 | (1,083 | ) | |||||
(Decrease) increase in accounts payable | (960 | ) | 11,859 | |||||
Increase (decrease) in customer prepayments | 11,527 | (21,453 | ) | |||||
(Decrease) increase in accrued program costs | (5,454 | ) | 12,285 | |||||
Decrease in other payables and accrued expenses | (8,180 | ) | (8,178 | ) | ||||
Net cash used in operating activities | (12,346 | ) | (27,144 | ) | ||||
Cash flows from investing activities: | ||||||||
Capital expenditures | (4,676 | ) | (2,398 | ) | ||||
Proceeds from disposal of property, plant and equipment | 10 | 492 | ||||||
Intangible assets | (5,149 | ) | (136 | ) | ||||
Net cash used in investing activities | (9,815 | ) | (2,042 | ) | ||||
Cash flows from financing activities: | ||||||||
Payments under line of credit agreement | (140,000 | ) | (179,415 | ) | ||||
Borrowings under line of credit agreement | 26,000 | 214,334 | ||||||
Borrowings under term loans | 225,000 | - | ||||||
Repayments of term loans | (1,125 | ) | - | |||||
Payment of deferred loan fees | (16,581 | ) | (3,339 | ) | ||||
Net receipt from the issuance of common stock under ESPP | 474 | 629 | ||||||
Net payment from common stock purchased for tax withholding | (99 | ) | (147 | ) | ||||
Net cash provided by financing activities | 93,669 | 32,062 | ||||||
Net increase in cash | 71,508 | 2,876 | ||||||
Effect of exchange rate changes on cash and cash equivalents | (24 | ) | 1,405 | |||||
Cash at beginning of period | 12,425 | 12,514 | ||||||
Cash at end of period | $ | 83,909 | $ | 16,795 | ||||
AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES
RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA
(In thousands)
(Unaudited)
For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net loss | $ | (17,668 | ) | $ | (12,358 | ) | $ | (31,682 | ) | $ | (21,669 | ) | ||||
| Provision for income taxes | 536 | 422 | 1,043 | 1,574 | ||||||||||||
| Interest expense, net | 9,146 | 4,920 | 24,066 | 13,135 | ||||||||||||
| Depreciation and amortization | 4,620 | 4,565 | 13,861 | 14,023 | ||||||||||||
| Stock compensation expense | 327 | 760 | 901 | 1,741 | ||||||||||||
| CFO transition costs | 1,316 | - | 1,316 | - | ||||||||||||
| Transformation costs | 1,665 | 1,442 | 5,975 | 5,254 | ||||||||||||
| Product liability claims & related expenses | 22 | 7,610 | 223 | 7,610 | ||||||||||||
| Asset impairments | - | 801 | 943 | 935 | ||||||||||||
| Other | 12 | 48 | 203 | (381 | ) | |||||||||||
| Adjusted EBITDA(1) | $ | (24 | ) | $ | 8,210 | $ | 16,849 | $ | 22,222 | |||||||
1 Adjusted earnings before interest, taxes, depreciation, and amortization (Adjusted EBITDA) is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net (loss) income, operating (loss) income or any other financial measure so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The items excluded from adjusted EBITDA are detailed in the reconciliation attached to this news release. Other companies (including the Company's competitors) may define adjusted EBITDA differently.
AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES
RECONCILIATION OF GAAP TO ADJUSTED OPERATING EXPENSES
(In thousands)
(Unaudited)
For the Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Operating expenses, as reported | $ | 34,217 | $ | 40,719 | ||||
Stock-based compensation(1) | (327 | ) | (760 | ) | ||||
Purchase accounting intangible amortization | (3,032 | ) | (3,065 | ) | ||||
Transformation costs(2) | (1,665 | ) | (1,442 | ) | ||||
Executive transition costs | (1,316 | ) | - | |||||
Asset impairments | - | (93 | ) | |||||
Product liability claims(3) | (22 | ) | (7,029 | ) | ||||
(Loss) gain on sale of assets | (75 | ) | 246 | |||||
| Non-GAAP adjustments to operating expenses | (6,437 | ) | (12,143 | ) | ||||
| Adjusted operating expenses(4) | $ | 27,780 | $ | 28,576 | ||||
1 We exclude stock-based compensation, which is non-cash, from the non-GAAP financial measures because the Company believes that such exclusion provides a better comparison of results of ongoing operations for current and future periods with such results from past periods.
2 Represents incremental consulting, severance, facility-rationalization, and systems-implementation costs under the Company's Transformation program, which management excludes as not indicative of ongoing operating performance.
3 Represents charges for specific product liability matters, net of expected insurance recoveries, which management excludes as not indicative of ongoing operating performance.
4 Adjusted operating expenses is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to operating expenses or any other financial measure so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The items excluded from Adjusted operating expenses are detailed in the reconciliation attached to this news release. Other companies (including the Company's competitors) may define Adjusted operating expenses differently.
SOURCE: American Vanguard
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were American Vanguard's third-quarter 2026 earnings results?
American Vanguard reported a $17.668 million net loss and a $0.61 loss per share for the quarter ended September 30, 2026. The prior-year quarter had a $12.358 million net loss and a $0.43 loss per share. Sales declined 9% to $108.376 million.
What is American Vanguard's revised full-year 2026 outlook?
American Vanguard expects $500 million to $530 million in sales and $36 million to $40 million in adjusted EBITDA for full-year 2026. Adjusted EBITDA is a non-GAAP measure that excludes interest, taxes, depreciation, amortization and certain other items.
Why did American Vanguard's third-quarter 2026 margins weaken?
American Vanguard attributed the pressure to lower international sales and higher raw-material and transportation costs, which more than offset lower operating costs and improved manufacturing efficiency. The company linked higher diesel and transportation costs to Middle East instability and said it was pursuing commercial actions to recover gross margins.